Responses with CAR T-cell therapy appear durable for non-Hodgkin lymphoma – Healio
|
Responses with CAR T-cell therapy appear durable for non-Hodgkin lymphoma
Healio ATLANTA — More than half of patients with refractory, aggressive non-Hodgkin lymphoma remained alive at least 1 year after receiving a single infusion of anti-CD19 chimeric antigen receptor T–cell therapy axicabtagene ciloleucel, according to updated … |
